» Articles » PMID: 17308306

The N-terminal Flanking Region of the TRP2360-368 Melanoma Antigen Determines Proteasome Activator PA28 Requirement for Epitope Liberation

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2007 Feb 20
PMID 17308306
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Proteasomes are known to produce major histocompatibility complex (MHC) class I ligands from endogenous antigens. The interferon-gamma-inducible proteasome activator PA28 plays an important role in the generation of MHC ligands by proteasomes. Generation of the HLA-A(*)0201 restricted melanoma antigen TRP2(360-368) by the proteasome has been shown to be dependent on the function of PA28 in vitro and in vivo (Sun, Y., Sijts, A. J., Song, M., Janek, K., Nussbaum, A. K., Kral, S., Schirle, M., Stevanovic, S., Paschen, A., Schild, H., Kloetzel, P. M., and Schadendorf, D. (2002) Cancer Res. 62, 2875-2882). Here we analyzed the role of the epitope sequence environment in determining this PA28 dependence. Experiments using the melanoma TRP2(288-296) epitope and the murine cytomegalovirus-derived pp89 epitope precursor peptide for epitope replacement revealed that the TRP2(360-368) flanking sequences can transfer PA28 dependence onto otherwise PA28 independent epitopes. Moreover, the N-terminal flanking sequence is sufficient to establish PA28 dependence of an epitope by allowing PA28-induced coordinated dual cleavages. These results show that N-terminal flanking sequences strongly influence epitope generation efficiency and that PA28 function is particularly relevant for the generation of normally poorly excised peptide products.

Citing Articles

Tumour neoantigen mimicry by microbial species in cancer immunotherapy.

Boesch M, Baty F, Rothschild S, Tamm M, Joerger M, Fruh M Br J Cancer. 2021; 125(3):313-323.

PMID: 33824481 PMC: 8329167. DOI: 10.1038/s41416-021-01365-2.


Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex.

Vigneron N, Van den Eynde B Biomolecules. 2014; 4(4):994-1025.

PMID: 25412285 PMC: 4279167. DOI: 10.3390/biom4040994.


Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients.

Mactier S, Kaufman K, Wang P, Crossett B, Pupo G, Kohnke P Pigment Cell Melanoma Res. 2014; 27(6):1106-16.

PMID: 24995518 PMC: 4285183. DOI: 10.1111/pcmr.12290.


Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.

Henle A, Erskine C, Benson L, Clynes R, Knutson K J Immunol. 2012; 190(1):479-88.

PMID: 23180824 PMC: 3529812. DOI: 10.4049/jimmunol.1201264.


Driving forces of proteasome-catalyzed peptide splicing in yeast and humans.

Mishto M, Goede A, Taube K, Keller C, Janek K, Henklein P Mol Cell Proteomics. 2012; 11(10):1008-23.

PMID: 22822185 PMC: 3494140. DOI: 10.1074/mcp.M112.020164.